NOV 06, 2016 3:48 PM PST

Drug for Neglected Disease Activated by Newly Found Enzyme

WRITTEN BY: Carmen Leitch
Neglected diseases are those that affect the world’s poor and are usually common in tropical areas. A new discovery could aid in the treatment of one such disease, Visceral leishmaniasis (VL) which is also known as Kala-azar. Researchers at the University of Dundee in New Zealand, an area of research on neglected diseases, have found a protein that can help improve the efficacy of a drug that was recently identified as a therapeutic for VL.
 

VL, described in the video above, that affects roughly two to four hundred thousand people globally, according to the Centers for Disease Control. It is a parasitic infection that can range from a silent infection, with no symptoms, to more serious cases of fever, weight loss and liver and spleen problems. It primarily affects people in Brazil, India, Nepal, Bangladesh, Ethiopia, South Sudan and Sudan. The current treatments have considerable limitations such as high cost, toxicity, side effects, prolonged administration and drug resistance; there are no vaccines.
 
"There has been considerable interest in developing new compounds to target diseases like leishmaniasis, particularly because the existing drugs are very unsatisfactory and increasingly becoming unusable due to resistance in the parasite," said Professor Alan Fairlamb, Wellcome Principal Research Fellow in the School of Life Sciences at Dundee. He is the senior author of the work, reported in PLOS Pathogens.
 
Fairlamb, in collaboration with Dr. Kevin Read and colleagues have previously shown that one drug used to treat tuberculosis, called delamanid, can potentially also treat VL. Their new work with a team at the Wellcome Trust Sanger Institute in Cambridge, UK, identified a protein that is characterized as a nitroreductase – an enzyme that targets nitrogen compounds, and shows that it can improve the efficacy of delamanid as a VL nitro-drug. An example of a nitroreductase is shown below.
 

 
The researchers term the newly found protein nitroreductase NTR2. The researchers show that it can result in hypersensitivity to bicyclic nitro compounds like delamanid. Another type of nitroreductase, NTR1, activates other types of nitrogen compounds, monocyclic nitro-drugs.
 
"One concern has been that if all nitro-drugs are activated by NTR1, then loss of this protein would lead to widespread drug resistance to both unicyclic drugs (fexinidazole) and bicyclic drugs (delamanid). We have discovered this new protein, NTR2 that specifically activates drugs like delamanid but not fexinidazole," explained Fairlamb
 
"This knowledge is extremely important in that it allows us to design better drugs activated by NTR2 and to suggest drug combinations that will reduce the risk of emergence of drug resistance through loss of either NTR1 or NTR2 activity. It also provides a potential diagnostic marker for resistance should it arise," said Fairlamb.
 
One drug identified by the researchers, fexinidazole, is undergoing phase II clinical trials in Africa as part of the Drugs for Neglected Diseases initiative. Delamanid has been considered for immediate trials in VL patients.
 
"Further work is now needed to find the most appropriate partner drugs to be used to increase efficacy and decrease toxicity in patients, to minimize the risk of drug resistance emerging and in designing second generation drugs.” Fairlamb concluded.

If you would like to know more about neglected disease of the world, watch the following video.
 

 
Sources: AAAS/Eurekalert! via Dundee University, PLOS Pathogens
 
About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 09, 2020
Cell & Molecular Biology
Why Liver Gene Therapies Have Not Worked & How to Improve Them
SEP 09, 2020
Why Liver Gene Therapies Have Not Worked & How to Improve Them
Diseases that are caused by errors in a gene might be cured if we could correct those errors, or genetic mutations.
SEP 11, 2020
Drug Discovery & Development
Single Injection Sends Type 2 Diabetes into Remission
SEP 11, 2020
Single Injection Sends Type 2 Diabetes into Remission
Type 2 diabetes affects around 10% of people in the US. Although there is no cure for it, there are some well-known meth ...
SEP 21, 2020
Cell & Molecular Biology
The Hormones We Have at Birth Are Linked to Disease Throughout Life
SEP 21, 2020
The Hormones We Have at Birth Are Linked to Disease Throughout Life
New work may help explain why some autoimmune or immune-related diseases are more common in women, who are more likely t ...
SEP 25, 2020
Cell & Molecular Biology
Researchers Take Organoids a Step Further
SEP 25, 2020
Researchers Take Organoids a Step Further
The human body is made of many different kinds of cells, which can often be cultured in a lab and studied. However, thos ...
OCT 26, 2020
Cancer
Investigating the Receptor Protein FPR1 in Brain Cancer
OCT 26, 2020
Investigating the Receptor Protein FPR1 in Brain Cancer
Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – us ...
OCT 28, 2020
Cell & Molecular Biology
Mimicking Cells With a Microfluidic Chip
OCT 28, 2020
Mimicking Cells With a Microfluidic Chip
Cell culture models are one way for scientists to learn more about biology. But cells grow in large cultures that are of ...
Loading Comments...